Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
470 JPY | -1.88% | -1.05% | -18.69% |
03:13pm | StemRIM to Seek Shareholders' Approval on Capital Stock Reduction | MT |
Mar. 13 | StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy | CI |
Sales 2024 * | 1B 6.42M | Sales 2025 * | 540M 3.47M | Capitalization | 28.9B 186M |
---|---|---|---|---|---|
Net income 2024 * | -1.29B -8.31M | Net income 2025 * | -1.68B -10.79M | EV / Sales 2024 * | 28.9 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 53.5 x |
P/E ratio 2024 * |
-22.6
x | P/E ratio 2025 * |
-17.5
x | Employees | 45 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 41.6% |
1 day | -1.88% | ||
1 week | -1.05% | ||
Current month | +0.86% | ||
3 months | -12.31% | ||
6 months | -33.05% | ||
Current year | -18.69% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 19-02-28 | |
Kensuke Tomita
CHM | Chairman | 75 | 13-06-30 |
Tomoyuki Hoshino
ADM | Chief Administrative Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 19-02-28 | |
Kensuke Tomita
CHM | Chairman | 75 | 13-06-30 |
Koichi Yokota
CTO | Chief Tech/Sci/R&D Officer | 66 | 13-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 470 | -1.88% | 119 900 |
24-05-08 | 479 | 0.00% | 123,400 |
24-05-07 | 479 | +0.84% | 151,900 |
24-05-02 | 475 | +0.42% | 177,500 |
24-05-01 | 473 | +1.50% | 203,600 |
Delayed Quote Japan Exchange, May 09, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.69% | 189M | |
-3.35% | 88.91B | |
+4.08% | 41.25B | |
-14.94% | 31.99B | |
+49.94% | 24.73B | |
-15.24% | 15.54B | |
-40.39% | 12.07B | |
-8.63% | 12.05B | |
-14.27% | 12.02B | |
+6.22% | 8.84B |
- Stock Market
- Equities
- 4599 Stock